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CASE STUDY




Primary central nervous system lymphoma (PCNSL) is a rare disease which accounts for 1–2 % of non-Hodgkin lym-
phoma and 3–5 % of primary brain tumor lesions. PCNSL of an immunocompetent patient is an uncommon disease, 
it is estimated at 4 % of new diagnoses of CNS tumors. The prognosis of PCNSL is poor compared to other extranodal 
lymphomas, with a 5-year survival estimated between 20 and 40 %. PCNSL relapse occurs either in the original site 
but still confined to the CNS or exceptionally outside it. Brain magnetic resonance imaging, although not allowing a 
clear distinction between primary lesions and secondary brain lymphoma is of paramount importance not only for 
diagnosis but also for monitoring the patient. This manuscript report the case of a patient in whom the PCNSL has 
relapsed in the cervical spinal cord and also in the liver.
Keywords: Primary central nervous system, Lymphoma, Liver, Relapse
© 2016 Igala. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made.
Background
Primary central nervous system lymphomas (PCNSLs) 
are rare diseases which account 1–2 % of non-Hodgkin 
lymphoma (NHL) and 3–5  % of primary brain tumor 
lesions (Ghesquières et  al. 2009; Sierra Del Rio et  al. 
2009). Their diagnosis requires that any other loca-
tion of systemic NHL is excluded (O’Neil et  al. 1995). 
PCNSL is usually classified as a diffuse large B cell lym-
phoma. It occurs frequently as congenitally acquired or 
in immunocompromised patients. It commonly involves 
frontal lobes, corpus callum, or deep periventricular 
structures; may involve eyes, meninges or spinal cord. 
The treatment remains poorly codified and involves 
drugs crossing the blood–brain barrier which can be 
administered intrathecally or intravenously, associated 
or not with radiotherapy. Surgery with the increased 
risks of complications in deep locations is not needed 
outside of stereotactic biopsy for diagnostic purposes 
(Abrey et  al. 2005). Relapses after treatment mostly 
occur in CNS, mainly leptomeningeal and ocular, <10 % 
are systemic. It report here a case of primary brain 
lymphoma relapse away from the primary lesion in the 
liver and in the CNS in an immunocompetent patient 
for whom the regular performance of positron emission 
tomography coupled to the scanner (PET/CT) and mag-
netic resonance imaging (MRI) has contributed to the 
diagnosis.
Case report
A 20 years old patient with no past medical history came 
to the hospital for a feeling of weakness in the right 
upper which limb appeared a few days earlier. On admis-
sion general examination was normal, performance sta-
tus was one with right hemiparesis. MRI reveals an oval 
left fronto-parietal lesion of 20 × 15 mm associated with 
significant peri-lesional edema (Fig.  1). A stereotactic 
biopsy was performed quickly, the histopathological 
analysis concluded an infiltration of the brain paren-
chyma by a diffuse large B-cells lymphoma, expressing 
the CD 20 antigen. The focus was then supplemented 
by serological testing which was all negatives (HIV, 
syphilitic, CMV, HBV, HCV), a bone marrow biopsy 
revealed no infiltration by lymphoma cell and was nega-
tive for CD20 or any other markers, immunophenotyp-
ing showed no monoclonal population and theslit-lamp 
eye examination was normal. PET/CT confirmed the 
absence of any lesion in favor of an extra-cerebral lym-
phomatous lesion.
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Chemotherapy with high-dose methotrexate (3500 mg/
m2) and cytarabine (2000 mg/m2) was administered.
The evolution was firstly favorable but 2  months later 
neurologicals signs reappeared and a new MRI concluded 
an increase of the mass, 41 × 24 versus 32 × 18 mm at the 
last control). PET/CT has not found any systemic lesion. 
A second line of chemotherapy with ifosfamide (2000 mg/
m2), coupled with radiotherapy was made with success but 
<1 month after the beginning of the treatment, the patient 
again presented with paresis of the right upper limb while 
the fronto-parietal brain injury declined. MRI of the 
whole spinal cord found an extending lesion from C2 to 
C4 (Fig. 2), which in this context, is suggestive of recur-
rence of lymphoma whereas no meningeal infiltration was 
found on lumbar puncture. It was decided to combine 
radiotherapy with temozolomide. PET/CT performed 
in conjunction confirmed the relapse, moreover, multi-
ple liver lesions were found (Fig.  3). Liver biopsy found 
a recurrence of diffuse large B-cell lymphoma expressing 
the CD20 antigen with a high proliferation index (Ki67 in 
95 % of tumor cells). Chemotherapy according to the pro-
tocol of the European Group of Lymphomas of the Adult 
(GELA): R-ACBVP (rituximab 375  mg/m2—adriamycin 
75  mg/m2—cyclophosphamide 1200  mg/m2—vindesine 
2 mg/m2—bleomycin 10 mg/m2—prednisone 60 mg/m2) 
was started but the patient died at the end of the second 
cycle of treatment.
Fig. 1 Brain MRI at diagnosis (a) and after two treatments by chemotherapy and radiotherapy (b)
Fig. 2 Medullary relapse of lymphoma
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Discussion
The PCNSL of immunocompetent patient is an uncom-
mon disease, it is estimated at 4  % of new diagnoses of 
CNS tumors. To diagnose CNSL, it is important to 
exclude other systemic NHL lesion, by conducting a 
number of tests as recommended by the GELA: a PET/
CT or CT scans of the thorax, abdomen and pelvis, a 
bone marrow biopsy, a peripheral blood immunophe-
notyping and testicular ultrasound in men (O’Neil et al. 
1995; Abrey et  al. 2005). In patient, the diagnosis of 
PCNSL cannot be challenged both at the beginning and 
in the relapse, as all systemic exams were negative.
The prognosis of PCNSL is poor compared to other 
extranodal lymphomas, with a 5-year survival estimated 
between 20 and 40  %. Relapses occur between the first 
and second year in 30–60 % of patients in complete remis-
sion. In the literature survival after relapse varies from 2 
to 4 months depending on the series (Jahnke et al. 2006).
PCNSL relapse occurs either in the original site but 
still confined to the CNS and exceptionally outside it. 
Jahnke et al. (2006) reported in a multicenter study 85 % 
of localized CNS relapse, 12  % systemic (nodal, muscu-
loskeletal, testicular, kidney structure and para-kidney 
and liver) and the rest of both systemic and plants. If the 
brain parenchyma is the most common site of relapse 
of PCNSL, our patient’s first relapse occured within the 
CNS, but in an unusual site of CNS: in the cervical spine. 
Jahnke et al. reported 6 % of similar cases. In general, sys-
temic relapse and in the liver in particular are very rare 
and few cases are reported.
Fig. 3 Comparaison of PET–CT at diagnosis (low) and liver  relapse (top)
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Brain MRI, although not allowing a clear distinction 
between primary lesions and secondary brain lymphoma, 
is of paramount importance not only for diagnosis but 
also for monitoring the patient (Senocak et  al. 2006). 
This is the strong clinical evidence that this exam result is 
important in diagnosis of the lymphomatous origin of the 
lesions observed in spite of the rarity of such evolution of 
the CNSL. Indeed, the cervical spinal cord although has 
a part of the CNS is not the usual location of PCNSL at 
diagnosis and his relapse.
In this case, the regular performance of PET/CT whole 
body has enabled us not only to confirm the nature of the 
primitive brain lymphoma (excluding when diagnosing 
any systemic involvement) but also it relapse in the cer-
vical spine and liver. PET/CT has a resolution more effi-
cient than conventional CT for the assessment of brain 
lymphoma as systemic lesions are identified much earlier 
(Mohil et al. 2008).
Although they have not been subject to confirmation 
by a phase III study, we opted for the first-line combi-
nation of high-dose MTX/cytarabine. In fact, these two 
agents have the advantage of crossing the blood–brain 
barrier in sufficient concentration to act on brain lym-
phoma lesions (Ferreri et al. 2002). Temozolomide for the 
choice of salvage treatment is related to the good results 
observed when using this drug in combination or not 
with radiotherapy for the treatment of relapsed or refrac-
tory PCNSL (Reni et al. 2007). The irradiation of the cer-
vical spine, with or without chemotherapy, usually used 
in recurrent meningitis in our patient resulted in the 
disappearance of localized lesions between C2 and C4 
(Rei and Ferreri 2001). Expression by lymphoma cells of 
CD 20 antigen drove us to use intravenous rituximab for 
the treatment of liver relapse according to the protocol 
R-ACBVP used in the treatment of high-grade NHL. A 
hope based on the use intrathecally this molecule in the 
treatment of relapsed CNSL, as suggested by the numer-
ous cases published in recent years (Hong et  al. 2009; 
Schulz et al. 2004; Watanabe et al. 2005; Pels et al. 2002).
Conclusion
PCNSL, of which the usual locations are eye, meningeal 
and parenchymal, is rare and has a poor prognosis. It can 
also relapse at a distance from the primary lesion. Sys-
temic relapse, poorly described so far, will receive a simi-
lar treatment to that of diffuse large cell NHL.
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